Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376039 | 0.98 | HSD17B10 (0.39) | HSD17B10LMNAALDH1A1KDM4CKDM4E | |
| SCHEMBL17294176 | 0.83 | ALDH1A1 (0.43) | HSD17B10LMNAALDH1A1KDM4CKDM4E | |
| SCHEMBL8614546 | 0.81 | ALDH1A1 (0.44) | HSD17B10LMNAALDH1A1KDM4CKDM4E | |
| SCHEMBL21292107 | 0.78 | ALDH1A1 (0.36) | HSD17B10LMNAALDH1A1KDM4CTSHR | |
| SCHEMBL21292112 | 0.77 | HSD17B10 (0.37) | HSD17B10LMNAALDH1A1KDM4CKDM4E | |
| SCHEMBL17536124 | 0.77 | TSHR (0.39) | HSD17B10LMNAALDH1A1KDM4CTSHR | |
| SCHEMBL6381411 | 0.75 | LMNA (0.42) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL642543 | 0.74 | TSHR (0.40) | HSD17B10LMNAALDH1A1KDM4CKDM4E | |
| SCHEMBL4779166 | 0.74 | HSD17B10 (0.35) | HSD17B10LMNAALDH1A1KDM4CKDM4E | |
| SCHEMBL6534645 | 0.72 | KDM4E (0.42) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464061-B2 | N-hydroxylamino-barbituric acid derivatives | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | NATIONAL SCIENCE FOUNDATION | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | TNNT2, TNNI3, TNNC1 | HSD17B10 607/4885LMNA 1383/4885ALDH1A1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.